Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Parents’ perspective on COVID-19 vaccine in children 6 months through 4 years: a cross-sectional study from Northwest Wisconsin
Mangat, Chetna , Rich, Jennifer, Sanghavi, Devang , Schmidt, Rebecca , Milosavljevic, Natasa, Linh, Tran , Bansal, Pankaj , Bansal, Pankaj , Rich, Jennifer, Schmidt, Rebecca

Mayo Clinic

BMJ Open | September 17, 2022 | Volume: 12 | Issue: 9 | Pages: e065453

10.1136/bmjopen-2022-065453 | PMID 36115680 Get It

Vaccination is critical to control the ongoing COVID-19 pandemic, but despite the availability of safe and effective vaccine in children over 5 years, vaccination rates remain low. There is paucity of data about vaccine acceptance and factors influencing parents’ hesitancy about the COVID-19 vaccine for young children. Aims and objectives To estimate vaccine acceptance by parents of children 6 months through 4 years, and to evaluate the factors influencing vaccine hesitancy. Methods Electronic survey was sent to parents of children 6 months through 4 years through an online portal account at Mayo Clinic Health System, Northwest-Wisconsin. Data were captured via Research Electronic Data Capture secured data collection software. Bivariate and multivariate regression was used to determine most pertinent factors influencing parents’ decisions against the outcome, ‘Intent to Vaccinate’. Results 39.7% of the parents were ‘very likely’ or ‘somewhat likely ’ to vaccinate their children once the vaccine became available, while 49.8% were not likely or highly unlikely to vaccinate. Routine childhood vaccination, receiving seasonal influenza vaccine, parents' perception of COVID-19 severity in children and safety and effectiveness of the vaccine were all associated with more vaccine acceptance. 71.4% of parents who will likely not vaccinate their children indicated that they are unlikely to change their decision. The need for more research on the vaccine and more information from the PCP office were the most common reasons behind the vaccine decision-making. Conclusions Vaccine hesitancy remains a major issue regarding uptake of the upcoming COVID-19 vaccine. Strong and clear evidence-based recommendations from primary care provider and more information from trusted websites such as Centers for Disease Control and Prevention can decrease vaccine hesitancy in parents. Further research targeted at understanding beliefs and perspectives of parents from different demographics can assist policy-makers in implementing measures to improve vaccination rates in children and tailor our dialogue to match the needs of our patients and families.
Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease
Kastl, Arthur , Weaver, Kimberly N. , Zhang, Xian , Strople, Jennifer A., Adler, Jeremy, Dubinsky, Marla C. , Bousvaros, Athos, Watkins, Runa , Dai, Xiangfeng , Chen, Wenli , Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Chun, Kelly , Zikry, Michael, Fernando, Manory, Bastidas, Monique, Hernandez, Cristian, Craig, Riley, Boccieri, Margie E., Firestine, Anne, Long, Millie D. , Kastl, Arthur J , Adler, Jeremy, Cross, Raymond K. , Ungaro, Ryan C. , Farraye, Francis A. , Bastidas, Monique, Boccieri, Margie , Firestine, Ann M. , Kappelman, Michael D. , Adler, J

Mayo Clinic

American Journal of Gastroenterology | September 17, 2022 | Volume: 118 | Issue: 1 | Pages: 129-137

10.14309/ajg.0000000000002016 | PMID 36114773 Get It

INTRODUCTION: Children with inflammatory bowel disease (IBD) may respond differently to COVID-19 immunization as compared with healthy children or adults with IBD. Those younger than 12 years receive a lower vaccine dose than adults. We sought to describe the safety and humoral immune response to COVID-19 vaccine in children with IBD. METHODS: We recruited children with IBD, ages 5–17 years, who received ≥ 2 doses of the BNT162b2 vaccine by a direct-to-patient outreach and at select sites. Patient demographics, IBD characteristics, medication use, and vaccine adverse events were collected. A subset of participants had quantitative measurement of anti-receptor binding domain IgG antibodies after 2-part immunization. RESULTS: Our study population included 280 participants. Only 1 participant required an ED visit or hospitalization because of an adverse event. Of 99 participants who underwent anti-receptor binding domain IgG antibody measurement, 98 had a detectable antibody, with a mean antibody level of 43.0 μg/mL (SD 67) and a median of 22 μg/mL (interquartile range 12–38). In adjusted analyses, older age ( P = 0.028) and antitumor necrosis factor monotherapy compared with immunomodulators alone ( P = 0.005) were associated with a decreased antibody level. Antibody response in patients treated with antitumor necrosis factor combination vs monotherapy was numerically lower but not significant. DISCUSSION: Humoral immune response to COVID-19 immunization in children with IBD was robust, despite a high proportion of this pediatric cohort being treated with immunosuppressive agents. Severe vaccine-related AEs were rare. Overall, these findings provide a high level of reassurance that pediatric patients with IBD respond well and safely to SARS-CoV-2 vaccination.
High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations
(DIAN), the Dominantly Inherited Alzheimer Consortia, Cilia, Roberto , Sharma, Jennifer , Schneider, Lon S. , Graff‐Radford, Neill R. , Mori, Hiroshi , Nübling, Georg, Andaloussi, Samir EL , Svenningsson, Per , Vöglein, Jonathan , Vöglein, Jonathan , Svenningsson, Per , Sturchio, Andrea , (DIAN), the Dominantly Inherited Alzheimer Consortia, Dwivedi, Alok , Malm, Tarja , Wood, Matthew J. A. , Hill, Emily J. , Nübling, Georg , Ezzat, Kariem , Espay, Alberto J.

Mayo Clinic

Journal of Alzheimer's Disease | September 16, 2022 | Volume: 90 | Issue: 1 | Pages: 333-348

10.3233/jad-220808 | PMID 36120786 Get It

Background: In amyloid-positive individuals at risk for Alzheimer’s disease (AD), high soluble 42-amino acid amyloid-β (Aβ42) levels are associated with normal cognition. It is unknown if this relationship applies longitudinally in a genetic cohort. Objective: To test the hypothesis that high Aβ42 preserves normal cognition in amyloid-positive individuals with Alzheimer’s disease (AD)-causing mutations (APP, PSEN1, or PSEN2) to a greater extent than lower levels of brain amyloid, cerebrospinal fluid (CSF) phosphorylated tau (p-tau), or total tau (t-tau). Methods: Cognitive progression was defined as any increase in Clinical Dementia Rating (CDR = 0, normal cognition; 0.5, very mild dementia; 1, mild dementia) over 3 years. Amyloid-positivity was defined as a standard uptake value ratio (SUVR) ≥1.42 by Pittsburgh compound-B positron emission tomography (PiB-PET). We used modified Poisson regression models to estimate relative risk (RR), adjusted for age at onset, sex, education, APOE4 status, and duration of follow-up. The results were confirmed with multiple sensitivity analyses, including Cox regression. Results: Of 232 mutation carriers, 108 were PiB-PET-positive at baseline, with 43 (39.8%) meeting criteria for progression after 3.3±2.0 years. Soluble Aβ42 levels were higher among CDR non-progressors than CDR progressors. Higher Aβ42 predicted a lower risk of progression (adjusted RR, 0.36; 95% confidence interval [CI], 0.19–0.67; p = 0.002) better than lower SUVR (RR, 0.81; 95% CI, 0.68–0.96; p = 0.018). CSF Aβ42 levels predicting lower risk of progression increased with higher SUVR levels. Conclusion: High CSF Aβ42 levels predict normal cognition in amyloid-positive individuals with AD-causing genetic mutations.
Perceived influence of medical school sexual health education on specialty selection in young urologists specializing in sexual dysfunction
Aro-Lambo, Mazeed , Vencill, Jennifer A. , Collins, Charles, Köhler, Tobias , Ziegelmann, Matthew , Parikh, Niki , Collins, Charles, Helo, Sevann

Mayo Clinic

No container title available | September 13, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1982068/v1 Get It

Abstract To determine effects of sexual health curriculum (SHC) in medical school on future urology specialty and subspecialty selection, residents, fellows, and practicing urologists completed a 15-question survey regarding their exposure to SHC during medical school, topics covered, and the influence of mentors in career choice. 95 respondents, primarily post-graduate year 4 and 5 (46%), completed the survey. Approximately 50% recalled dedicated SHC during medical school with 46% planning to pursue fellowship training in sexual medicine/reconstruction. Topics commonly covered included reproductive anatomy/physiology and sexual history-taking, while respondents rarely recalled topics such as sexual aids/toys and pornography. Only 25% felt SHC provided an adequate fund of knowledge to address patient’s sexual health concerns, and only 14% believed SHC influenced their decision to pursue urology. Individuals pursuing fellowship were more likely to have an attending mentor, a mentor with expertise in sexual dysfunction, and considered their mentor as important or very important in their decision to subspecialize (p<0.05). Most urology trainees do not have strong exposure to SHC during medical school and cite mentorship as more important in the decision to pursue subspecialty training. These data support the need for a standardized formal SHC and continued exposure to sexual health experts during training.
Real-World Outcomes in Patients with First-Line and Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma
Ahn, Daniel H. , Sidel, Michelle, Panattoni, Laura , Sacks, Naomi , Hernandez, Jennifer , Villacorta, Reginald , Ahn, Daniel H , Villacorta, Reginald

Mayo Clinic

Future Oncology | September 13, 2022 | Volume: 18 | Issue: 30 | Pages: 3419-3433

10.2217/fon-2022-0708 | PMID 36098270 Get It

The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation
Arthurs, Jennifer R. , Lillie, Charlene M. Martin, Martin Lillie, Charlene M, Lillie, Charlene M Martin, Master, Zubin , Shapiro, Shane A.

Mayo Clinic

Journal of Primary Care & Community Health | September 13, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221121460 | PMID 36112830 Get It

Introduction: Direct to consumer stem cell and regenerative interventions (SCRIs) for various medical conditions have increased in popularity due to unmet medical needs and the promise of SCRIs to meet those needs. These interventions may have varying levels of safety and efficacy data and many lack sufficient scientific data to be marketed. The direct to consumer SCRI industry has received significant attention due to potential physical, economic, and emotional harms to patients. Patients may seek the counsel of their primary care providers when considering stem cell therapy for their condition. Methods: Here we describe strategies primary care providers can utilize when counseling patients. Results: Although we recommend constructing these discussions around individual patients’ needs, one can utilize a general approach consisting of 4 parts. First, providers should recognize what information the patient is seeking and what is their understanding of stem cell and regenerative medicine. Next, providers should convey evidence-based information at the level of patients understanding so that they are aware of the risks, benefits, and descriptions of possible procedures. Throughout the conversations, attempts should be made to guide patients to a trusted resource that can provide additional information. Finally, providers should make an effort to address misinformation in a way that is nonjudgmental and patient-centered to make the patient feel safe and comfortable. Conclusion: Effectively communicating risk information by primary care providers to patients is important given the harms reported from direct-to-consumer SCRIs. Correcting misinformation remains a priority when discussing SCRI’s. Providers should strive to offer patients with additional resources such as the opportunity for consultation with a specialist or a consultation service dedicated to informing patients about regenerative medicine.
MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls
Gaudioso, Cristina , Mar, Soe , Casper, T. Charles , Codden, Rachel , Nguyen, Adam, Aaen, Gregory , Chitnis, Tanuja , Francisco, Carla , Gorman, Mark , Greenberg, Benjamin , Hart, Janace, Lotze, Timothy , Narula, Sona , Pittock, Sean J. , Rose, John , Schreiner, Teri , Tillema, Jan‐Mendelt , Wheeler, Yolanda , Gaudioso, Cristina M , Chitnis, Tanuja , Graves, Jennifer , Pittock, S J , Waubant, Emmanuelle L. , Greenberg, Benjamin M , Nguyen, Adam, Benson, Leslie, Goyal, Manu S. , Graves, Jennifer , Krupp, Lauren , Rensel, Mary R. , Rodriguez, Moses , Schreiner, Teri , Waldman, Amy , Weinstock‐Guttman, Bianca , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | September 11, 2022 | Volume: 93 | Issue: 2 | Pages: 271-284

10.1002/ana.26502 | PMID 36088544 Get It

Objective The purpose of this study was to determine the frequency of myelin oligodendrocyte glycoprotein (MOG)‐IgG and aquaporin‐4 (AQP4)‐IgG among patients with pediatric‐onset multiple sclerosis (POMS) and healthy controls, to determine whether seropositive cases fulfilled their respective diagnostic criteria, to compare characteristics and outcomes in children with POMS versus MOG‐IgG‐associated disease (MOGAD), and identify clinical features associated with final diagnosis. Methods Patients with POMS and healthy controls were enrolled at 14 US sites through a prospective case–control study on POMS risk factors. Serum AQP4‐IgG and MOG‐IgG were assessed using live cell‐based assays. Results AQP4‐IgG was negative among all 1,196 participants, 493 with POMS and 703 healthy controls. MOG‐IgG was positive in 30 of 493 cases (6%) and zero controls. Twenty‐five of 30 patients positive with MOG‐IgG (83%) had MOGAD, whereas 5 of 30 (17%) maintained a diagnosis of multiple sclerosis (MS) on re‐review of records. MOGAD cases were more commonly in female patients (21/25 [84%] vs 301/468 [64%]; p = 0.044), younger age (mean = 8.2 ± 4.2 vs 14.7 ± 2.6 years; p < 0.001), more commonly had initial optic nerve symptoms (16/25 [64%] vs 129/391 [33%]; p = 0.002), or acute disseminated encephalomyelitis (ADEM; 8/25 [32%] vs 9/468 [2%]; p < 0.001), and less commonly had initial spinal cord symptoms (3/20 [15%] vs 194/381 [51%]; p = 0.002), serum Epstein–Barr virus (EBV) positivity (11/25 [44%] vs 445/468 [95%]; p < 0.001), or cerebrospinal fluid oligoclonal bands (5/25 [20%] vs 243/352 [69%]; p < 0.001). Interpretation MOG‐IgG and AQP4‐IgG were not identified among healthy controls confirming their high specificity for pediatric central nervous system (CNS) demyelinating disease. Five percent of those with prior POMS diagnoses ultimately had MOGAD; and none had AQP4‐IgG positivity. Clinical features associated with a final diagnosis of MOGAD in those with suspected MS included initial ADEM phenotype, younger age at disease onset, and lack of EBV exposure. ANN NEUROL 2023;93:271–284
Efficacy and safety of lamotrigine in pediatric mood disorders: A systematic review
Kumar, Rakesh , Garzon, Juan F. , Yuruk, Deniz , Hassett, Leslie C. , Saliba, Maria , Özger, Can , Oztosun, Cinar , Ahern, Kelly B. , Athreya, Arjun P. , Singh, Balwinder , Voort, Jennifer L. Vande , Garzon, Juan, Ahern, Kelly, Croarkin, Paul E , Vande Voort, Jennifer L , Singh, Balwinder , Kumar, Rakesh , Hassett, Leslie C , Croarkin, Paul E.

Mayo Clinic

Acta Psychiatrica Scandinavica | September 10, 2022 | Volume: 147 | Issue: 3 | Pages: 248-256

10.1111/acps.13500 | PMID 36086813 Get It

Abstract Aim To appraise the current evidence on the efficacy and safety of lamotrigine (LAM) in the treatment of pediatric mood disorders (PMD) (i.e., Major Depressive disorder [MDD], bipolar disorder [BD]). Methods Major databases were searched for randomized controlled trials (RCTs), open‐label trials, and observational studies reporting on pediatric (age < 18 years) patients treated with LAM for mood disorders. Results A total of 3061 abstracts were screened and seven articles were selected for inclusion. Seven studies (319 BD and 43 MDD patients), including one RCT ( n = 173), three prospective ( n = 105), and three retrospective ( n = 84) studies, met the study criteria with a study duration range from 8 to 60.9 weeks. The mean age of this pooled data is 14.6 ± 2.0 years. LAM daily dosage varied from 12.5 to 391.3 mg/day among the studies. In an important finding, the RCT reported favorable outcomes with LAM (HR = 0.46; p = 0.02) in 13‐ to 17‐year‐old age group as compared with 10‐ to 12‐year‐old age group (HR = 0.93; p = 0.88). In addition, time to occurrence of a bipolar event trended toward favoring LAM over placebo. All the studies identified LAM as an effective and safe drug in PMDs especially, BDs. Overall, LAM was well tolerated with no major significant side effects and no cases of Stevens–Johnson syndrome. Conclusions Most studies suggested that LAM was safe and effective in pediatric patients with mood disorders. However, the data regarding the therapeutic range for LAM are lacking. Based on the data, there is inconsistent evidence to make conclusive recommendations on therapeutic LAM dosage for mood improvement in the pediatric population. Further studies including larger sample sizes are required to address this relevant clinical question.
Detection of Dementia Signals from Longitudinal Clinical Visits Using One-Class Classification
Ibrahim, Omar A. , Vassilaki, Maria , Petersen, Ronald C. , Sohn, Sunghwan , St Sauver, Jennifer, Fu, Sunyang , Mielke, Michelle M. , Sauver, Jennifer L. St.

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 211-216

10.1109/ichi54592.2022.00040 | PMID 36484060 Get It

FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
Abdelrahman, Amro M. , Goenka, Ajit H. , Leiting, Jennifer L. , Merrell, Kenneth W. , Hallemeier, Christopher L. , Haddock, Michael G. , Smoot, Rory L. , Nagorney, David M. , Kendrick, Michael L. , Truty, Mark J. , Smoot, Rory L , Abdelrahman, Amro M , Alva‐Ruiz, Roberto , Yonkus, Jennifer A. , Graham, Rondell P. , Thiels, Cornelius A. , Hallemeier, Christopher Leigh , Warner, Susanne G. , Grotz, Travis E. , Tran, Nguyen H., Wee, Wen , Cleary, Sean P. , McWilliams, Robert R. , Hálfdánarson, Þorvarður R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 1023-1032.e3

10.6004/jnccn.2022.7041 | PMID 36075389 Get It

Background: Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly predicts response, and biochemical (CA 19-9) markers are not useful (nonsecretors/nonelevated) in many patients. Pathologic response highly predicts survival post-NAT, but is only known postoperatively. Because metabolic imaging (FDG-PET) reveals primary tumor viability, this study aimed to evaluate our experience with preoperative FDG-PET in patients with BR/LA PDAC in predicting NAT response and survival. Methods: We reviewed all patients with resected BR/LA PDAC who underwent NAT with FDG-PET within 60 days of resection. Pre- and post-NAT metabolic (FDG-PET) and biochemical (CA 19-9) responses were dichotomized in addition to pathologic responses. We compared post-NAT metabolic and biochemical responses as preoperative predictors of pathologic responses and recurrence-free survival (RFS) and overall survival (OS). Results: We identified 202 eligible patients. Post-NAT, 58% of patients had optimization of CA 19-9 levels. Major metabolic and pathologic responses were present in 51% and 38% of patients, respectively. Median RFS and OS times were 21 and 48.7 months, respectively. Metabolic response was superior to biochemical response in predicting pathologic response (area under the curve, 0.86 vs 0.75; P <.001). Metabolic response was the only univariate preoperative predictor of OS (odds ratio, 0.25; 95% CI, 0.13–0.40), and was highly correlated ( P =.001) with pathologic response as opposed to biochemical response alone. After multivariate adjustment, metabolic response was the single largest independent preoperative predictor ( P <.001) for pathologic response (odds ratio, 43.2; 95% CI, 16.9–153.2), RFS (hazard ratio, 0.37; 95% CI, 0.2–0.6), and OS (hazard ratio, 0.21; 95% CI, 0.1–0.4). Conclusions: Among patients with post-NAT resected BR/LA PDAC, FDG-PET highly predicts pathologic response and survival, superior to biochemical responses alone. Given the poor ability of anatomic imaging or biochemical markers to assess NAT responses in these patients, FDG-PET is a preoperative metric of NAT efficacy, thereby allowing potential therapeutic alterations and surgical treatment decisions. We suggest that FDG-PET should be an adjunct and recommended modality during the NAT phase of care for these patients.